GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting

Author's Avatar
Nov 03, 2022

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that data from two investigator-sponsored trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting.